Last update Oct. 14, 2024
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Maternal Hyperthyroidism is also known as
Maternal Hyperthyroidism belongs to this group or family:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Hyperthyroidism occurs in 1 to 2 out of every 1,000 pregnancies (Inoue 2009) with Graves' disease being the most frequent cause (85%: Marx 2008). It often improves in the third trimester of pregnancy allowing reduction or withdrawal of medication and usually worsens after delivery, requiring reinstatement or reinforcement of treatment, which is safe for the infant whether it is continued from gestation or established during lactation and does not require monitoring of the infant's thyroid function, it is sufficient to control the adequate physical and psychomotor development. (Alexander 2017, Inoue 2009, Marx 2008, Mandel 2001)
There is general consensus among authors and specialized societies to give treatment without interrupting lactation (Ashkar 2023, Dumitrascu 2021, Romeo 2020, Cuff 2019, Alexander 2017, Poppe 2012, Lazarus 2012, Mestman 2012). It is convenient to administer the medication immediately after a breastfeeding. (Ashkar 2023, Hudzik 2016)
There are no data to support that hyperthyroidism can affect milk production or lactation in general. (Alexander 2017)
Postpartum thyroiditis, with its clinical phases of hyper- and hypothyroidism, is an autoimmune-caused inflammation that occurs in the first year after delivery, with an incidence of 3 to 16% (Serrano 2014, Muller 2001). There are no data to recommend universal screening but there is in women with type 1 diabetes mellitus or associated depression (Abalovich 2007). During the hypothyroid phase of postpartum thyroiditis, levothyroxine may need to be added, especially if symptoms are present, they are breastfeeding or trying to become pregnant. (Cuff 2019)
Hyperthyrodism is associated with increased risk of breast cancer, especially if associated with overweight and/or duration of breastfeeding less than 6 months.(Yang 2020)
There is controversy about its association with hyperprolactinemia. (Sanjari 2016, Onal 2014)
Anti-TSH receptor antibodies (TRAb) can be found in milk from mothers treated for thyrotoxicosis in the first two months, and may cause transient thyroid disease in the infant (Törnhage 2006), usually hyperthyroidism that may require treatment. (Azizi 2011)
During pregnancy and lactation iodine requirements are increased, being about 250 micrograms (μ) daily and not exceeding 500 μ daily (Southern 2024, Alexander 2017, Serrano 2014, Stagnaro 2011, Abalovich 2007). In areas with severe iodine deficiency and no use of iodized salt, postpartum administration of a single oral dose of 400 mg of iodized oil ensures an adequate amount of iodine in breast milk for 6 months. (Bouhouch 2014)
See below the information of these related products: